In silico designing and optimization of anti-breast cancer antibody mimetic oligopeptide targeting HER-2 in women

Journal of Molecular Graphics and Modelling

Volumn 28, Issue 7, 2010, Pages 664-669

  Akhoon, Bashir A ^a   Gupta, Shishir K ^b   Verma, Vijeshwar ^a   Dhaliwal, Gagan ^b   Srivastava, Mugdha ^b   Gupta, Shailendra K ^c   Ahmad, Raja Feroz ^a  

^a SHRI MATA VAISHNO DEVI UNIVERSITY   (India)

^b Society for Biological Research and Rural Development   (India)

^c CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

Author keywords

Anticancer drug; Breast cancer; HER 2; Oligopeptide designing; Pertuzumab

Indexed keywords

ANTICANCER DRUG; APOPTOSIS INDUCTION; BINDING POCKETS; BREAST CANCER; BREAST CANCER CELLS; DIMERIZATION DOMAIN; EXTRACELLULAR DOMAINS; HUMANIZED ANTIBODY; HUMANIZED MONOCLONAL ANTIBODY; IN-SILICO; OLIGOPEPTIDES; OVER-EXPRESSION; SPECIFIC INTERACTION; TARGET DOMAIN; TRANSMEMBRANES;

BINDING ENERGY; BIOCHEMISTRY; CELL DEATH; GROWTH KINETICS; MONOCLONAL ANTIBODIES;

BINDING SITES;

AMINO ACID; ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; OLIGOPEPTIDE; PERTUZUMAB;

APOPTOSIS; ARTICLE; BINDING AFFINITY; BINDING SITE; BREAST CANCER; CANCER GROWTH; CELL GROWTH; COMPUTER AIDED DESIGN; CONTROLLED STUDY; DRUG BINDING; DRUG INHIBITION; GENE OVEREXPRESSION; HYDROGEN BOND; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; BREAST NEOPLASMS; COMPUTATIONAL BIOLOGY; DRUG DESIGN; FEMALE; HUMANS; ISOELECTRIC POINT; MODELS, MOLECULAR; MOLECULAR MIMICRY; MOLECULAR SEQUENCE DATA; OLIGOPEPTIDES; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, ERBB-2; THERMODYNAMICS;

EID: 76549090936     PISSN: 10933263     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmgm.2010.01.002     Document Type: Article

References (19)

1. http://www.cancer.org
2. Matthew C.F., Kendall D.C., Felix F.V., Daniel J.L., de vos Abraham M., and Mark X.S. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5 (2004) 317-328
3. Kurebayashi J., Otsuki T., Tang C.K., Kurosumi M., Yamamoto S., Tanaka K., Mochizuki M., Nakamura H., and Sonoo H. Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the ErbB family receptors and interleukin-6. Br. J. Cancer 79 (1999) 707-717
4. Morrow P., Zambrana F., and Esteva F.J. Recent advances in systemic therapy: advances in systemic therapy for HER2-positive metastatic breast cancer. Breast Cancer Res. 11 (2009) 207
5. Salem M., Kinoshita Y., Tajiri T., Souzaki R., Tatsuta K., Higashi M., Izaki T., Kohashi K., Tsuneyoshi M., and Taguchi T. Association between the HER2 expression and histological differentiation in Wilms tumor. Pediatr. Surg. Int. 22 (2006) 891-896
6. Fiegl H., Millinger S., Goebel G., Holzner E., Marth C., Laird P.W., and Widschwendter M. Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Res. 66 (2006) 29-33
7. Hiroo N., Naruhiko M., Koichi S., Ikuya F., Atsushi Y., Satoshi T., Ryoko T., and Seiichi T. Development of HER2-antagonistic peptides as novel anti-breast cancer drugs by in silico methods. Breast Cancer 72 (2008) 15-65
8. Dailey M.M., Hait C., Holt P.A., Maguire J.M., Meier J.B., Miller M.C., and Petraccone L. Trent JO structure-based drug design: from nucleic acid to membrane protein targets. Exp. Mol. Pathol. 86 (2009) 141-150
9. Laskoswki R.A., MacArthur M.W., Moss D.S., and Thornton J.M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Cryst. 26 (1993) 283-291
10. Lüthy R., Bowie J.U., and Eisenberg D. Assessment of protein models with three dimensional profiles. Nature 356 (1992) 83-85
11. Maupetit J., Derreumaux P., and Tuffery P. PEP-FOLD: an online resource for de novo peptide structure prediction. Nucleic Acids Res. 37 (2009) 498-503
12. Maupetit J., Derreumaux P., and Tuffery P. A fast and accurate method for large-scale de novo peptide structure prediction. J. Comput. Chem. (2009)
13. Kaur H., Garg A., and Raghava G.P. PEPstr: a de novo method for tertiary structure prediction of small bioactive peptides. Protein Pept. Lett. 14 (2007) 626-631
14. Camproux A.C., Tuffery P., Chevrolat J.P., Boisvieux J.F., and Hazout S. Hidden Markov model approach for identifying the modular framework of the protein backbone. Protein Eng. 12 (1999) 1063-1073
15. Camproux A.C., Gautier R., and Tuffery P. A hidden Markov model derived structural alphabet for proteins. J. Mol. Biol. 339 (2004) 591-605
16. Tuffery P., Guyon F., and Derreumaux P. Improved greedy algorithm for protein structure reconstruction. J. Comput. Chem. 26 (2005) 506-513
17. Tuffery P., and Derreumaux P. Dependency between consecutive local conformations helps assemble protein structures from secondary structures using Go potential and greedy algorithm. Proteins 61 (2005) 732-740
18. Maupetit J., Tuffery P., and Derreumaux P. A coarse-grained protein force field for folding and structure prediction. Proteins 69 (2007) 394-408
19. Gupta S.K., Singh A., Srivastava M., Gupta S.K., and Akhoon B.A. In silico DNA vaccine designing against human papillomavirus (HPV) causing cervical cancer. Vaccine 28 (2009) 120-131